Five health and tech companies went public this week, and each finished the week up at least 20%. One SPAC also IPO'd. Three companies and one SPAC submitted initial filings.
After weeks of nonstop news coverage, The We Company (WE) delayed its IPO to the...read more
Exagen, which sells blood tests that can diagnose, prognose, or monitor autoimmune diseases, raised $50 million by offering 3.6 million shares at $14, the low end of the range of $14 to $16. The company offered an additional 266,667 shares to maintain its deal...read more
Five IPOs and one SPAC plan to raise $1.7 billion in the week ahead. Rumors are swirling that The We Company (WE) will launch its long-awaited IPO. Datadog (DDOG) will join the year's growing list of VC-backed...read more
Exagen, which sells blood tests that can diagnose, prognose, or monitor autoimmune diseases, announced terms for its IPO on Monday. The Vista, CA-based company plans to raise $50 million by offering 3.3 million shares at a price range of $14 to $16. At the...read more
US IPO Weekly Recap: Health and tech shine as week’s 5 IPOs close Friday up 20% or more
Five health and tech companies went public this week, and each finished the week up at least 20%. One SPAC also IPO'd. Three companies and one SPAC submitted initial filings. After weeks of nonstop news coverage, The We Company (WE) delayed its IPO to the...read more
Diagnostics provider Exagen prices $50 million IPO at $14, the low end of the range
Exagen, which sells blood tests that can diagnose, prognose, or monitor autoimmune diseases, raised $50 million by offering 3.6 million shares at $14, the low end of the range of $14 to $16. The company offered an additional 266,667 shares to maintain its deal...read more
US IPO Week Ahead: Datadog chases $7 billion valuation in 5-IPO week
Five IPOs and one SPAC plan to raise $1.7 billion in the week ahead. Rumors are swirling that The We Company (WE) will launch its long-awaited IPO. Datadog (DDOG) will join the year's growing list of VC-backed...read more
Diagnostic test maker Exagen sets terms for $50 million IPO
Exagen, which sells blood tests that can diagnose, prognose, or monitor autoimmune diseases, announced terms for its IPO on Monday. The Vista, CA-based company plans to raise $50 million by offering 3.3 million shares at a price range of $14 to $16. At the...read more